HARMONi-10 Phase 3 Trial for Ivonescimab
HARMONi-10 Phase 3 Trial for Ivonescimab
Conclusion: HARMONi-10 is a global, open-label Phase 3 trial asking whether ivonescimab (Summit's PD-1×VEGF bispecific) beats durvalumab as consolidation therapy after chemoradiation in unresectable Stage III NSCLC. Its primary endpoint is progression-free survival (PFS). It is positioned as potentially registration-enabling, but it starts after a CRL that said PFS alone was not enough for the current application. The trial's value depends on whether it can deliver a PFS win that the FDA will accept, which probably requires a credible overall survival (OS) signal. Investors should treat it as a long-dated option on the program, not a near-term catalyst. Site activation was only guided to begin in Q4 2026.
Data as of: 2026-11-19 (Asia/Shanghai), covering announcements through 2026-11-18 US Eastern. I did not pull a current quote, and this note does not assess the share price.
What the trial is designed to answer
- Population: adults with locally advanced, unresectable Stage III NSCLC who have not progressed after platinum-based concurrent chemoradiation. Per the registry summary, the enrolment target is . A French registry entry lists participants. I could not reconcile these, so I treat the 167 figure as the only unverified target.
- Comparison: ivonescimab versus durvalumab, the current standard consolidation therapy after chemoradiation. The company calls it "head-to-head" against standard-of-care PD-L1 therapy.
- Primary endpoint: PFS. The company did not state the OS design in the material I reviewed, so I cannot confirm whether OS is a key secondary endpoint.
- Eligibility, per the French registry, excludes EGFR-mutant tumours and patients with prior PD-1/PD-L1 or anti-angiogenic exposure. PD-L1 status is required but not restricted by level. The trial therefore targets a population outside the approved-pathway question in the CRL.
Where it fits in the program
- HARMONi-10 is Summit's sixth sponsored Phase 3 study of ivonescimab and its fourth in NSCLC, after HARMONi, HARMONi-3 and HARMONi-7 (press release). It moves the NSCLC strategy earlier in disease, from metastatic EGFR-mutant (HARMONi) to first-line metastatic (HARMONi-3, HARMONi-7) to consolidation (HARMONi-10).
- The regulatory backdrop matters. On 2026-11-15, the FDA issued a CRL for the HARMONi-based BLA, saying "substantial evidence of effectiveness is not established in the absence of a statistically significant overall survival (OS) improvement" (Summit press release; 8-K).
- The OS history explains the CRL. In HARMONi, the primary OS hazard ratio in the Western subgroup was (Fierce Pharma). A later June 2026 cut reported across the full population and the Western subgroup, but this was a post-hoc analysis, and the FDA did not accept it as sufficient.
- The PFS result in HARMONi was median, with a hazard ratio of , in randomised patients (Healio). The FDA's position is that a PFS benefit without significant OS does not support approval.
- My read: HARMONi-10 is a rational next step for the franchise, but it is a bet that the PFS signal translates into a registrable result in a different setting. The OS lesson from the CRL is directly relevant, since a PFS-primary design with a 1:1 open-label comparison may face the same evidentiary question.
Milestones to monitor
- Site activation and first patient dosed, guided to begin Q4 2026 (press release). Slippage would signal execution or enrolment problems.
- Final squamous PFS analysis in HARMONi-3 by year-end 2026, and nonsquamous PFS in 1H 2027, per Fierce Pharma. HARMONi-3 is the first-line test that Leerink analysts flagged as the real test for the class. An April 2026 interim analysis of the squamous cohort missed statistical significance on PFS.
- FDA path after the CRL: whether Summit requests a Type A meeting, resubmits, or waits for OS data. Any statement on the OS requirement is the key regulatory signal.
- Trial design disclosures: the OS endpoint, interim analysis timing, and the sample size on ClinicalTrials.gov, which I could not verify in the sources I reviewed.
- Financing: Fierce Pharma reports a $2 billion AstraZeneca investment weeks before the CRL. I did not verify this against a primary release, so treat it as unconfirmed until checked against Summit's filings.
Risks
- Regulatory: the FDA has stated that PFS without significant OS is insufficient. HARMONi-10 has a PFS primary, so the same objection could apply even if it succeeds.
- Clinical: Stage III consolidation is a different setting from metastatic disease, and the comparator is an established standard. Benefit may be smaller, and the trial is open-label, which invites bias concerns in PFS assessment.
- Competitive: Pfizer, BioNTech/BMS, Merck and AbbVie are advancing their own PD-(L)1×VEGF bispecifics into global Phase 3 trials (Fierce Pharma). First-mover advantage has narrowed.
- Concentration: ivonescimab is Summit's core asset, and Akeso (HKEX 9926) developed it. Summit's commercial leadership changed shortly before the CRL, per Fierce Pharma.
- Data reliability: the Phase 3 data cited are largely from Summit and Akeso releases. The China-only trials are positive but are not the global data the FDA reviewed.
Sources
- Summit Therapeutics, "Further Expands Ivonescimab Global Development Program with Phase III HARMONi-10 Study," 2026-11-18: https://smmttx.com/news/press-releases/news-details/2026/Summit-Therapeutics-Further-Expands-Ivonescimab-Global-Development-Program-with-Phase-III-HARMONi-10-Study-in-Unresectable-Stage-III-Non-Small-Cell-Lung-Cancer/default.aspx
- Summit Therapeutics Form 8-K, 2026-11-18 (HARMONi-10 announcement): https://www.sec.gov/Archives/edgar/data/1599298/000159929826000094/smmt-20261118.htm
- Summit Therapeutics, "Provides Update Regarding Ivonescimab BLA" (CRL), 2026-11-15: https://www.businesswire.com/news/home/20261115117181/en/Summit-Therapeutics-Provides-Update-Regarding-Ivonescimab-Biologics-License-Application?feedref=JjAwJuNHiystnCoBq_hl-QyNsUQ29c24MKpwrFSKUOTZQK86VRF04E6aMvZHPoaH7fxFuNFTHSunhvli30RlBNXya2izy9YOgHlBiZQk2LP6oD-t3eB0qV-nJQ-WeFyCEq7XOd8em_Uy42DWNTo2Mw%3D%3D
- Summit Therapeutics Form 8-K, 2026-11-16 (CRL): https://www.sec.gov/Archives/edgar/data/1599298/000159929826000092/smmt-20261115.htm
- Healio, "FDA rejects ivonescimab...," 2026-11-16: https://www.healio.com/news/hematology-oncology/20261116/fda-rejects-ivonescimab-for-egfrmutated-locally-advanced-or-metastatic-nsclc
- Fierce Pharma (Angus Liu), "FDA rejects Summit's ivonescimab...," 2026-11-15: https://www.fiercepharma.com/pharma/fda-rejects-summit-therapeutics-pd-1-vegf-ivonescimab-nsclc
- Patient.info registry summary for HARMONi-10 (secondary; enrolment target and start date 06 Nov 2026): https://patient.info/research/trials/locally-advanced-unresectable-non-small--2026-526300-67-00
- Santé.fr registry entry for HARMONi-10 (French; eligibility and "18 participants" figure): https://www.sante.fr/essais-cliniques/2026-526300-67-00/etude-de-phase-iii-en-ouvert-comparant-l-ivonescimab-au-durvalumab-en-tant-que-traitement-de-consolidation-chez-des-patients-atteints-d-un-cancer-du-poumon-non-a-petites-cellules-localement-avance-et-inoperable-stade-iii-n-ayant-pas-presente-de-progression-de-la-maladie-apres-un-traitement-definitif-par-chimioradiotherapie-concomitante-a-base-de-platine-harmoni-10
- ClinicalTrials.gov NCT05899608 (HARMONi-3 record; status and completion dates): https://clinicaltrials.gov/study/NCT05899608